Clinical Trials Logo

Hypothalamic Obesity clinical trials

View clinical trials related to Hypothalamic Obesity.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06299891 Not yet recruiting - Craniopharyngioma Clinical Trials

Efficacy and Safety of Phentermine/Topiramate in Youth With Hypothalamic Obesity

Start date: May 1, 2024
Phase: Phase 2
Study type: Interventional

Hypothalamic obesity (HO) refers to the substantial weight gain that often complicates hypothalamic brain tumors. Children with this treatment-recalcitrant form of obesity have excess rates of metabolic sequelae compared to otherwise healthy children with similar obesity, and later experience excess mortality related to cardiometabolic disease. In this pilot trial, our objective is to gather key preliminary data about phentermine/topiramate (Ph/T) that is FDA-approved for "common" obesity but has never been tested in HO. The subset of individuals with HO who experience hyperphagia or excess daytime sleepiness may benefit from the Ph/T-induced decrease in appetite and increase in alertness. Preliminary assessments of safety, adverse events, dosing (Aim 1), as well as of efficacy (% BMI loss, Aim 2) will be made in a 28-week parallel-arm double-blinded Phase 2 placebo-controlled clinical trial in 12-28-year-old individuals with HO.

NCT ID: NCT06046443 Not yet recruiting - Clinical trials for Hypothalamic Obesity

A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity

Start date: June 17, 2024
Phase: Phase 2
Study type: Interventional

The goal of this study is to determine how well LB54640 works and how safe it is in patients with Hypothalamic Obesity (HO). The study will evaluate the effect of LB54640 on safety, weight reduction, hunger, and quality of life in patients 12 years of age and older with HO. Patients will take an oral daily dose of either LB54640 (low, middle, or high dose) or placebo through Week 14. Eligible patients who consent to continue in the study after Week 14 will take an oral daily dose of LB54640 through Week 56.